Leading the way in palmitoylation-targeted therapeutics

Palmitoylation is an activating post-translational modification that is essential for the function of many proteins involved in numerous pathophysiological pathways

The PalmReader Platform

Our proprietary screening technology is the only high-throughput method for the detection of protein palmitoylation. PalmReader allows us to identify novel palmitoylation-modulating molecules thousands of times faster than current methods and has unlocked palmitoylation-targeted drug development for the first time.

“We have differentiated ourselves by exploiting a previously inaccessible area of biology called protein palmitoylation. While the functional role of palmitoylation is well established in numerous diseases, methods to selectively drug this modification have been underexplored. Palm was founded with the mission of unlocking the therapeutic potential of this space and developing the first palmitoylation-targeted drugs.”

— Andrew Rudd | Cofounder & CEO

Recent News

  • Palm Therapeutics Awarded Curebound Catalyst Grant

    Sep. 24, 2024

    Read More

  • Palm Therapeutics Selected as a 2024 Cool Company by Connect

    Apr. 8th, 2024

    Read More

  • Embracing Novel Frontiers: Tachyon Ventures' First Investment in Palm Therapeutics

    Jan. 25th, 2024

    Read More

  • Palm Therapeutics Presents at CLS Innovation Showcase

    Dec. 12th, 2023

    Read More

  • Palm Wins Servier Discovery Award

    Sep. 30th, 2023

    Read More

  • Palm Selected for California Life Sciences FAST Program

    Sep. 20th, 2023

    Read More

  • Palm Tx Drug Discovery Platform Highlighted by J&J Innovation

    Apr. 11th, 2023

    Read More
All News